About Acerta Pharma

In February 2016, AstraZeneca made a multibillion-dollar investment in Acerta Pharma for 55% ownership, driven by the lead investigational Bruton tyrosine kinase (BTK) inhibitor, acalabrutinib and the opportunity to build out its hematology/oncology pipeline. AstraZeneca holds the option to purchase the remainder of Acerta Pharma and complete a full acquisition.

Acerta Pharma’s discovery and research teams, which focus on developing new molecular entities, are based in Oss, The Netherlands. The group there was responsible for the discovery of acalabrutinib. Our largest site, which includes clinical operations, medical science, regulatory, safety, compliance, biostatistics, medical affairs and US administration is located in South San Francisco, CA.

The acalabrutinib program includes multiple clinical trials for both monotherapy and in combination with other targeted molecules. Over 200 employees are engaged in the development of acalabrutinib and other pipeline compounds for hematologic malignancies.

Plans to expand the oncology program include testing other targeted compounds in combination with acalabrutinib in a variety of blood based oncology indications.

Our Leadership

 

Jurriaan Dekkers photo

Jurriaan Dekkers

Chief Executive Officer

Ed Tucker photo

Edwin J. Tucker, MD, MBA

Chief Operating Officer

Andrew Mortlock photo

Andrew Mortlock, PhD

Chief Scientific Officer

Functional Leaders

 

Tjeerd Barf photo

Tjeerd Barf, PhD

Executive Vice President – Chemistry and Oss Site Head

Davy Chiodin photo

Davy Chiodin, PharmD

Vice President – Regulatory Science and Quality Assurance

Ed Clark photo

Ed Clark, PhD

Executive Director and Senior Project Leader

Todd Covey photo

Todd Covey

Vice President for Biology

Melanie Frigault photo

Mélanie M. Frigault, PhD

Head of Translational Science

Ahmed Hamdy photo

Ahmed Hamdy, MD

Vice President and Head Early Clinical Development

Raquel Izumi photo

Raquel Izumi, PhD

Executive Vice President for Early Phase Regulatory Affairs and Development

Priti Patel photo

Priti Patel, MD

Vice President, Hematology Development

Emily Roberts-Thomson photo

Emily Roberts-Thomson, MMedSci

Vice President – Clinical Operations

Joe Stalder photo

Joe Stalder, PharmD

Head of Project Management

Nico Stam photo

Nico Stam, PhD, MBA

Vice President Europe & Site Head Acerta Oss, Netherlands

Joseph Ware photo

Joseph Ware, PhD

Senior Director of Quantitative Clinical Pharmacology

Fan Zhang photo

Fan Zhang, PhD

Vice President, Head of Biometrics

Board of Directors

 

Pascal Soriot photo

Pascal Soriot

Executive Director and Chief Executive Officer – AstraZeneca plc

Marc Dunoyer photo

Marc Dunoyer

Executive Director and Chief Financial Officer – AstraZeneca plc

Jurriaan Dekkers photo

Jurriaan Dekkers

Chief Executive Officer

Nico Stam photo

Nico Stam, PhD, MBA

Vice President Europe & Site Head Acerta Oss, Netherlands

Founders

Acerta Pharma thanks its founders for their efforts, sacrifices and dedication to bringing acalabrutinib to patients.

Our founders image

Ahmed Hamdy, MD

Medical

Allard Kaptein, PhD

Discovery

Raquel Izumi, PhD

Clinical Operations

Tjeerd Barf, PhD

Chemistry

Francisco Salva

Finance & Operations